Korro Bio, Inc. (KRRO)
(Delayed Data from NSDQ)
$42.19 USD
-4.80 (-10.21%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $42.56 +0.37 (0.88%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRRO 42.19 -4.80(-10.21%)
Will KRRO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for KRRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRRO
Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade
Best Momentum Stocks to Buy for February 16th
KRRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for February 16th
Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?
Other News for KRRO
option delistings on June 3rd
Korro to Participate in Upcoming June Investor and Scientific Conferences
Buy Rating Affirmed for Korro Bio Amid Promising KRRO-110 Preclinical Data and Superior Therapeutic Profile
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference